Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071602
Filing Date
2025-05-14
Accepted
2025-05-14 17:13:04
Documents
72
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q aldx-20250331.htm   iXBRL 10-Q 2029927
2 EX-31.1 aldx-ex31_1.htm EX-31.1 18034
3 EX-31.2 aldx-ex31_2.htm EX-31.2 18063
4 EX-32.1 aldx-ex32_1.htm EX-32.1 13839
5 GRAPHIC img131808304_0.jpg GRAPHIC 215270
  Complete submission text file 0000950170-25-071602.txt   8056075

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aldx-20250331.xsd EX-101.SCH 978155
75 EXTRACTED XBRL INSTANCE DOCUMENT aldx-20250331_htm.xml XML 1205344
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36332 | Film No.: 25947046
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)